Prospector
Profile
3-25-003
|
| |
| Valeant Pharmaceuticals International |
NAICS |
325412 |
| One Enterprise,
Aliso Viejo, CA 92656 |
Description |
Pharmaceutical Preparations |
| (949) 461-6000 |
Employees |
3001 |
| http://www.valeant.com/ |
Revenue |
(mil) |
872.2200 |
| |
Income |
(mil) |
-6.1900 |
| |
Assets |
(mil) |
1494.2600 |
| |
Liability |
(mil) |
1080.1600 |
| |
(for the year ended 2007-12-31) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
Valeant Pharmaceuticals International reported a net loss of $6.2 million on total revenues of $872.2 million for the year ended December 31, 2007, compared with a net loss of $57.6 million on total revenues of $862.8 million for the year ended December 31, 2006. At December 31, 2007, the Company's consolidated balance sheet showed $1.49 billion in total assets, $1.08 billion in total liabilities, and $414.1 million in total shareholders' equity.
|
| |
|
Intellectual Property:
The Company owns a United States composition of matter patent (which will expire in 2013) directed to retigabine without regard to crystalline form. The Company also owns two United States patents that are directed to specific crystalline forms of retigabine (both of which will expire in 2018). In addition, it owns a number of United States patents and pending applications, with expiration dates ranging from 2016 to 2023, directed to the use of retigabine to treat a variety of disease indications. The Company also owns several patents and pending applications in foreign countries with expiration dates ranging from 2012 to 2024. The Company owns a United States patent (which will expire in 2018) directed to a method of treating a viral infection using a genus of compounds that includes taribavirin. It also owns a United States patent (which will expire in 2020) that specifically claims the use of taribavirin to treat hepatitis C infection. If taribavirin receives regulatory approval, these patents may be eligible for patent term extensions. To the extent permitted in foreign jurisdictions, the Company is pursuing the foreign patent rights that correspond to its United States patents. Upon regulatory approval, the Company expects to obtain five years of data exclusivity in the United States and eight years in Europe for retigabine and taribavirin. The Company has various issued patents or pending applications in foreign countries. These patents or patent applications, if issued, have expiration dates ranging from 2012 to 2023. [SEC Filing 10-K 03-17-08]
|
| |
|
Description:
Valeant Pharmaceuticals International develops, manufactures and markets various pharmaceutical products in the areas of neurology, infectious diseases and dermatology worldwide.
|
| |
|
Officers:
J. Michael Pearson (Chair & CEO); Peter J. Blott (EVP & CFO); Robert A. Ingram (Dir.); Richard H. Koppes (Dir.) Lawrence N. Kugelman (Dir.); Theo Melas-Kyriazi (Dir.); G. Mason Morfit (Dir.); Norma A. Provencio (Dir.)
|
| |
|
Auditor:
PricewaterhouseCoopers LLP
|
| |
|
Securities:
Common Stock Symbol VRX; NYSE; 89,286,410 common shares outstanding as of March 11, 2008.
|
| |
| |
| |
| return to main page |
